公式財務諸表に基づく売上高、利益、キャッシュフローの推移。
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→
| 損益計算書 | TTM → 2026-03-31 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 | 2018-06-30 | 2017-06-30 | 2016-06-30 | 2015-06-30 | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 | 2009-06-30 | 2008-06-30 | 2007-06-30 | 2006-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 売上高合計 | $1.2B | $1.2B | $1.2B | $1.1B | $1.1B | $931M | $739M | $714M | $643M | $563M | $499M | $452M | $358M | $311M | $315M | $290M | $269M | $264M | $257M | $223M | $203M |
| 売上総利益 | $786M | $790M | $770M | $770M | $756M | $633M | $483M | $473M | $432M | $375M | $337M | $307M | $251M | $231M | $236M | $225M | $215M | $208M | $205M | $177M | $157M |
| 売上総利益率 % | 65.0% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% | 67.5% | 67.9% | 70.3% | 74.4% | 75.0% | 77.6% | 79.8% | 79.0% | 79.5% | 79.1% | 77.4% |
| 営業利益（EBIT） | $154M | $102M | $207M | $299M | $297M | $237M | $157M | $126M | $136M | $122M | $151M | $147M | $160M | $158M | $166M | $163M | $156M | $151M | $144M | $124M | $109M |
| 営業利益率 % | 12.7% | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% | 17.6% | 21.2% | 21.6% | 30.2% | 32.5% | 44.6% | 51.0% | 52.8% | 56.2% | 58.1% | 57.1% | 56.0% | 55.5% | 53.5% |
| 当期純利益 | $110M | $73M | $168M | $285M | $272M | $140M | $229M | $96M | $125M | $77M | $104M | $108M | $111M | $113M | $112M | $112M | $110M | $105M | $104M | $85M | $73M |
| 純利益率 % | 9.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.5% | 13.7% | 20.9% | 23.8% | 31.0% | 36.2% | 35.7% | 38.7% | 40.8% | 39.9% | 40.2% | 38.1% | 36.2% |
| EBITDA | $258M | $217M | $313M | $457M | $414M | $250M | $378M | $212M | $201M | $182M | $193M | $184M | $179M | $173M | $175M | $174M | $165M | $159M | $152M | $137M | $115M |
| 1株当たり利益（EPS） | $0.70 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.45 | $0.62 | $0.82 | $0.52 | $0.70 | $0.72 | $0.75 | $0.76 | $0.76 | $0.76 | $0.73 | $0.69 | $0.66 | $0.54 | $0.46 |
| 発行済株式数（百万株） | 157M | 160M | 161M | 162M | 164M | 162M | 158M | 156M | 152M | 150M | 149M | 149M | 148M | 148M | 148M | 149M | 149M | 152M | 157M | 158M | 158M |
出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。
貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は TECH のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/TECH
本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。
About TickerBase · Data methodology & sources · Privacy · Terms